|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
6 months
2 months
4 months
|
|
gptkbp:approvedBy
|
1998
|
|
gptkbp:brand
|
gptkb:Rotarix
gptkb:RotaTeq
gptkb:Rotavac
Rotasiil
|
|
gptkbp:broadcastOn
|
oral drops
|
|
gptkbp:contraindication
|
severe allergic reaction to previous dose
immunodeficiency
history of intussusception
|
|
gptkbp:costEffectiveness
|
high
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Brazil
gptkb:India
gptkb:South_Africa
gptkb:United_Kingdom
gptkb:United_States
many other countries
|
|
gptkbp:developedBy
|
gptkb:Bharat_Biotech
gptkb:Merck_&_Co.
gptkb:Serum_Institute_of_India
GlaxoSmithKline
|
|
gptkbp:effect
|
high in preventing severe rotavirus disease
lower in low-income countries
|
|
gptkbp:form
|
oral suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rotavirus vaccine
|
|
gptkbp:includedIn
|
national immunization programs
|
|
gptkbp:prevention
|
rotavirus gastroenteritis
rotavirus infection
|
|
gptkbp:publicHealthConcern
|
significant reduction in diarrheal deaths
|
|
gptkbp:recommendation
|
gptkb:Centers_for_Disease_Control_and_Prevention
gptkb:World_Health_Organization
|
|
gptkbp:reduces
|
childhood mortality
hospitalization due to diarrhea
|
|
gptkbp:restored
|
2006
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
irritability
intussusception (rare)
mild diarrhea
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:targetAudience
|
infants
|
|
gptkbp:type
|
live attenuated vaccine
|
|
gptkbp:usedIn
|
children
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:withdrawn
|
1999
|
|
gptkbp:bfsParent
|
gptkb:Gastroenteritis
|
|
gptkbp:bfsLayer
|
5
|